ライフサイエンスコーパス: intraocular pressure

1 r more incisional procedures to control high intraocular pressure.

2 procedures and devices that aim to decrease intraocular pressure.

3 (SC), for maintaining appropriate levels of intraocular pressure.

4 0.0003) while adjusting for age, gender, and intraocular pressure.

5 habitually treated with eye drops that lower intraocular pressure.

6 gible and showed vitreous seeding and normal intraocular pressure.

7 ly contribute to altered aqueous outflow and intraocular pressure.

8 space for aqueous drainage and reduction of intraocular pressure.

9 rring around the stent and subsequent raised intraocular pressure.

10 indness that occurs without grossly abnormal intraocular pressure.

11 eous humor outflow and maintenance of normal intraocular pressure.

12 1%, P < .001) and postoperative elevation of intraocular pressure (11.6% vs DSAEK 23.6% vs PK 22.5%,

13 embrane (13.2%), glaucoma (11.3%), increased intraocular pressure (8.5%), and severe inflammation (6.

14 beculectomy showed a significant decrease in intraocular pressure (-9.2 mmHg, p<.001) when compared t

15 erative antibiotics, and 31% routinely check intraocular pressure after injection.

16 eview of culture results, visual acuity, and intraocular pressure also was performed for patients wit

17 that of another two groups (P < 0.001) while intraocular pressure and biometry data were similar.

18 Intraocular pressure and glaucoma medications were also

19 Intraocular pressure and ICP were recorded simultaneousl

20 Intraocular pressure and medication data were recorded a

21 n active storage machine (ASM) that restores intraocular pressure and medium renewal.

22 Control individuals had no elevated intraocular pressure and no signs of glaucoma.

23 ed with older age, Russian ethnicity, higher intraocular pressure and open-angle glaucoma.

24 l role in shaping the cornea with respect to intraocular pressure and physical interventions.

25 sion was comparable to that observed between intraocular pressure and structural progression (OR, 1.3

26 Five eyes demonstrated elevated intraocular pressure, and 4 eyes demonstrated a retinal

27 oss, best spectacle-corrected visual acuity, intraocular pressure, and glaucoma medications/surgeries

28 s used to determine the change in CDVA, CST, intraocular pressure, and hard exudate area over time.

29 A fifth of the patients required control of intraocular pressure, and new-onset cataract developed i

30 elial cell density, corneal thickness, haze, intraocular pressure, and visual function before and 12

31 range of eye sizes, scleral thicknesses and intraocular pressures, and target sites relevant for epi

32 microbeads was made in mouse eyes to elevate intraocular pressure as a model of experimental glaucoma

33 y to enhance ocular fluid outflow and reduce intraocular pressure as a treatment for glaucoma, one of

34 Elevated intraocular pressure as the result of abnormal resistanc

35 loplasty group required no drops to maintain intraocular pressure at target.

36 After adjusting for age, gender, ethnicity, intraocular pressure, axial length and corneal curvature

37 maging of the optic disc and measurements of intraocular pressure, axial length, and refractive error

38 Intraocular pressure, baseline pRNFL thickness, baseline

39 Intraocular pressure before SLT was 21.9+/-5.2 mmHg whil

40 We found no differences in intraocular pressure between individual mouse groups.

41 ation showed unilaterally severely increased intraocular pressure, bilateral dense pigment deposition

42 ral or clear superior wound, does not affect intraocular pressure, bleb morphology or function after

43 s macaque monkey model following increase in intraocular pressure by an intravitreal injection.

44 TM) physiological role is to maintain normal intraocular pressure by regulating aqueous humor outflow

45 otential ocular side effects (e.g., elevated intraocular pressure, cataracts).

46 y lower rate of graft rejection and elevated intraocular pressure compared to DSAEK and PK for the sa

47 in-the-bag intraocular lens implantation on intraocular pressure control and the bleb morphology in

48 of internal drainage (widefield viewing and intraocular pressure control using continuous anterior c

49 uccessfully placed in both eyes and adequate intraocular pressure control was achieved for 4 months.

50 tions are a common method of achieving early intraocular pressure control with ligated glaucoma drain

51 months later was performed for uncontrolled intraocular pressure despite antihypertensive drugs comb

52 There is significant increase in intraocular pressure due to prone positioning among acut

53 Intraocular pressure during follow-up significantly affe

54 such post-vitrectomy cases may contribute to intraocular pressure elevation and increased risk of gla

55 Intraocular pressure elevation of more than 25 mmHg was

56 Intraocular pressure elevation was not observed in exper

57 increases the risk of corticosteroid-induced intraocular pressure elevation, suggesting common geneti

58 ed to the stressed projection in response to intraocular pressure elevation.

59 nd dark adaptometer for mesopic conditions), intraocular pressure, endothelial cell density (ECD) and

60 After nominal return of intraocular pressure, focal defects in flow persisted, w

61 At the last visit, the mean intraocular pressure for the temporal group was 17.55 +/

62 To prevent daily fluctuations in intraocular pressure for vulnerable glaucoma patients, i

63 Outcome measures included reduction in intraocular pressure from baseline, survival analysis, a

64 Increases in intraocular pressure from IVI have the potential to affe

65 pic effects with vertical cup-to-disc ratio, intraocular pressure, glaucoma and myopia.

66 The story of physicians' attempts to assess intraocular pressure goes back many centuries.

67 lmologic evaluation including measurement of intraocular pressure, gonioscopy, dilated fundus examina

68 Criteria for PG were PDS and 2 of 3 signs: intraocular pressure >21 mm Hg, glaucomatous optic nerve

69 All NGON patients with intraocular pressure >21 mm Hg, narrow drainage angles,

70 of the eye examination, ocular hypertension (intraocular pressure >23 mm Hg, Goldmann applanation ton

71 Two of these patients had an intraocular pressure >30 mm Hg.

72 laucoma surgery have been developed to lower intraocular pressure in a less invasive manner than trad

73 Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cat

74 Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cat

75 ous solubility with therapeutic reduction of intraocular pressure in murine glaucoma models.

76 We elevated intraocular pressure in one eye and determined how astro

77 Intraocular pressure in the left eye was mildly elevated

78 Intraocular pressure (in mm Hg) measured by hand-held ap

79 Median intraocular pressure increased significantly (p <= 0.001

80 Intraocular pressure increases as early as 10 minutes af

81 umulative failure of the AADI was defined as intraocular pressure (IOP) >18 mm Hg or not reduced by 3

82 me was time until device failure, defined as intraocular pressure (IOP) >21 mmHg or a reduction <20%,

83 month surgical failure, which was defined as intraocular pressure (IOP) >21 mmHg with medications or

84 ere categorized by percentage of visits with intraocular pressure (IOP) <18 mmHg or by average IOP.

85 te success at 9 months, which was defined as intraocular pressure (IOP) <=18, 15 or 12 mmHg without t

86 ere identified, and data of patients who had intraocular pressure (IOP) <=21 mm Hg at 6 weeks (ie, th

87 Cumulative success at 2 years was defined as intraocular pressure (IOP) <=21 mm Hg or reduced by >=20

88 outcome measure was success rate, defined as intraocular pressure (IOP) <=21 mm Hg with a minimum of

89 glaucoma, 12-month follow-up, and medicated intraocular pressure (IOP) <=36 mmHg on <=4 medications

90 ing selection criteria: Caucasian ethnicity, intraocular pressure (IOP) 21-40 mm Hg, cup:disc ratio >

91 Glaucomatous eyes with an intraocular pressure (IOP) above target and/or progressi

92 Intraocular pressure (IOP) and cataract formation were d

93 s, time to reinjections, visual acuity (VA), intraocular pressure (IOP) and central retinal thickness

94 Visual acuity (VA), intraocular pressure (IOP) and complications associated

95 he eye tissue responsible for maintenance of intraocular pressure (IOP) and development of Glaucoma.

96 association of habitual caffeine intake with intraocular pressure (IOP) and glaucoma and whether gene

97 We measured treatment effect as reduction in intraocular pressure (IOP) and mean medication use and e

98 Outcome measures included intraocular pressure (IOP) and number of antiglaucoma me

99 ed by an open anterior chamber angle, raised intraocular pressure (IOP) and optic nerve damage leadin

100 ecular meshwork (TM) damage and elevation of intraocular pressure (IOP) are poorly understood.

101 icroelectronic sensor that measures habitual intraocular pressure (IOP) at any given time and promise

102 Success was defined as intraocular pressure (IOP) between 6 and 21 mmHg (criter

103 nstrate that DBA/2J.Wld(s) mice develop high intraocular pressure (IOP) but are protected from retina

104 Chronic elevations in intraocular pressure (IOP) can cause blindness by compro

105 Elevation of intraocular pressure (IOP) causes retinal ganglion cell

106 medication, and NLS + medication) on 1-year intraocular pressure (IOP) change.

107 g aqueous outflow from the eye, resulting in intraocular pressure (IOP) changes that are variable in

108 perative hypertensive phase and on long-term intraocular pressure (IOP) control after Ahmed glaucoma

109 sual symptoms, (3) treatment burden, and (4) intraocular pressure (IOP) control, but unlike patients

110 were excluded if LTP laterality or baseline intraocular pressure (IOP) could not be determined.

111 ts included demographic information, vision, intraocular pressure (IOP) data before and after surgery

112 Elevated intraocular pressure (IOP) due to insufficient aqueous h

113 Adjustment for intraocular pressure (IOP) elevation during follow-up on

114 k (TM) is associated with TM dysfunction and intraocular pressure (IOP) elevation in glaucoma.

115 Intraocular pressure (IOP) elevation was relatively rapi

116 ondary graft failure, endothelial rejection, intraocular pressure (IOP) elevation, and the need for a

117 Intraocular pressure (IOP) elevations may occur in early

118 ME, best-corrected visual acuity (BCVA), and intraocular pressure (IOP) events over 24 weeks.

119 The change in intraocular pressure (IOP) from baseline to 12 months wa

120 The primary outcome was reduction of intraocular pressure (IOP) from baseline.

121 Failure was defined as an intraocular pressure (IOP) greater than 21 mmHg or IOP r

122 a complex tissue responsible for maintaining intraocular pressure (IOP) homeostasis.

123 resented with an acute asymmetrical raise in intraocular pressure (IOP) immediately following a famil

124 ns of the retina and are injured by elevated intraocular pressure (IOP) in diseases such as glaucoma.

125 y/Phacoviscocanalostomy (VC/PVC) in lowering intraocular pressure (IOP) in Normal Tension Glaucoma (N

126 acoemulsification has been linked to lowered intraocular pressure (IOP) in patients with glaucoma, oc

127 oplasty (SLT) is a common procedure to lower intraocular pressure (IOP) in patients with glaucoma.

128 f cataract surgery by phacoemulsification on intraocular pressure (IOP) in patients with medically PO

129 ce of automated visual field (VF) testing on intraocular pressure (IOP) in patients with ocular hyper

130 each active component, in reducing elevated intraocular pressure (IOP) in patients with open-angle g

131 ciations between systemic medication use and intraocular pressure (IOP) in the general population.

132 Postoperative complications were intraocular pressure (IOP) increase (n = 12), cystoid ma

133 s and preserve visual function after severe, intraocular pressure (IOP) induced ischemia in rat.

134 Elevated intraocular pressure (IOP) is a major risk factor for gl

135 Elevated intraocular pressure (IOP) is a major risk factor for th

136 While intraocular pressure (IOP) is a well-known risk factor f

137 An elevated intraocular pressure (IOP) is considered to be the main

138 Accurate determination of intraocular pressure (IOP) is crucial for the diagnosis

139 Intraocular pressure (IOP) is maintained as a result of

140 Elevated intraocular pressure (IOP) is the major risk factor for

141 Postoperative intraocular pressure (IOP) less than or equal to 24 mm H

142 Main outcome measures were postoperative intraocular pressure (IOP) level and secondary measures

143 fectiveness of various glaucoma surgeries on intraocular pressure (IOP) management in ARS.

144 lved, among other procedures, VF testing and intraocular pressure (IOP) measurement at 11 scheduled v

145 performed, including indentation gonioscopy, intraocular pressure (IOP) measurement, optic disc exami

146 Central corneal thickness influences intraocular pressure (IOP) measurement.

147 Repeated intraocular pressure (IOP) measurements were performed b

148 libercept group included 4 participants with intraocular pressure (IOP) more than 10 mm Hg greater th

149 is the rate of surgical failure, defined as intraocular pressure (IOP) more than 21 mmHg or reduced

150 Elevated intraocular pressure (IOP) narrows Schlemm's canal (SC),

151 Surgical success was defined as an intraocular pressure (IOP) of 5-20 mm Hg and no addition

152 Patients older than 18 years with intraocular pressure (IOP) of more than 18 mmHg for whom

153 was the rate of surgical failure, defined as intraocular pressure (IOP) of more than 21 mmHg or reduc

154 Eleven cases (2.6%) had an intraocular pressure (IOP) over 30 mm Hg at POD1.

155 Intraocular pressure (IOP) readings were obtained by Gol

156 within episcleral veins was correlated with intraocular pressure (IOP) reduction and change in visua

157 Intraocular pressure (IOP) reduction prevents developmen

158 Increased intraocular pressure (IOP) represents a major risk facto

159 Icare(R) HOME allows intraocular pressure (IOP) sampling by the patient.

160 e of the second generation of an implantable intraocular pressure (IOP) sensor in patients with prima

161 Three intraocular pressure (IOP) success cutoffs were defined:

162 retion and the drainage of AH determines the intraocular pressure (IOP) that is the major casual risk

163 ising corneal biomechanical properties under intraocular pressure (IOP) to help better understand ocu

164 aucoma has been established by elevating the intraocular pressure (IOP) via microbead occlusion of oc

165 The mean intraocular pressure (IOP) was 14.88 +/- 3.34 (6-25) mmH

166 y outcome, whereas difference in the rise in intraocular pressure (IOP) was a secondary outcome.

167 er goniopuncture was done in cases where the intraocular pressure (IOP) was elevated above 21 mmHg af

168 Intraocular pressure (IOP) was lowered surgically in 2 i

169 Intraocular pressure (IOP) was measured using a Goldmann

170 Intraocular pressure (IOP) was measured with the partici

171 Success was defined as complete when intraocular pressure (IOP) was more than 5 mmHg and less

172 Intraocular pressure (IOP) was significantly lower 1 wee

173 Intraocular pressure (IOP) was similar for both study gr

174 E), and postoperative visual acuity (VA) and intraocular pressure (IOP) were obtained.

175 ICP and intraocular pressure (IOP) were simultaneously measured

176 (PTM), total energy delivered, and baseline intraocular pressure (IOP) with success.

177 work (TM) is an ocular tissue that maintains intraocular pressure (IOP) within a physiologic range.

178 sted for confounding factors, including age, intraocular pressure (IOP), and choroidal thickness.

179 for gestational age, optic nerve appearance, intraocular pressure (IOP), and sequelae of prematurity.

180 rans pars plana vitrectomies (PPV's) and the intraocular pressure (IOP), and the effect of multiple P

181 Its stiffness, along with intraocular pressure (IOP), are linked to several pathol

182 Intraocular pressure (IOP), best corrected visual acuity

183 hart review; main outcome measures: anatomy, intraocular pressure (IOP), best visual acuity (BVA).

184 st follow-up were identified, including age, intraocular pressure (IOP), central corneal thickness (C

185 istory, best-corrected visual acuity (BCVA), intraocular pressure (IOP), clinical presentation, eye c

186 is a system for the continual monitoring of intraocular pressure (IOP), composed of an intraocular s

187 on, slit-lamp examination, optical biometry, intraocular pressure (IOP), endothelial cell count and p

188 Preoperative and postoperative intraocular pressure (IOP), extent of angle treated, pos

189 timal approach for continuous measurement of intraocular pressure (IOP), including pressure transduce

190 The effects of postinjection elevation of intraocular pressure (IOP), injection frequency, and num

191 aucoma outcome was assessed by postoperative intraocular pressure (IOP), number of medications, and n

192 retrospective study the relationship between intraocular pressure (IOP), retinal nerve fiber layer (R

193 Visual acuity, intraocular pressure (IOP), survival of corneal grafts,

194 The intraocular pressure (IOP), the active substances of the

195 d control eyes were similar in terms of mean intraocular pressure (IOP), the proportion of eyes meeti

196 ve clinical data, outcome measures including intraocular pressure (IOP), use of glaucoma medications,

197 leads to ocular hypertension, i.e., elevated intraocular pressure (IOP), which, in turn, can progress

198 y uncontrolled glaucoma as indicated by high intraocular pressure (IOP), worsening visual field, or o

199 ubsequent metabolic studies characterized an intraocular pressure (IOP)-dependent decline in retinal

200 To evaluate the safety and intraocular pressure (IOP)-lowering effect of a biodegra

201 To characterize the 12-month intraocular pressure (IOP)-lowering efficacy of selectiv

202 Primary outcome measure was intraocular pressure (IOP).

203 topical steroids which in turn may increase intraocular pressure (IOP).

204 flow facility correlates with an increase in intraocular pressure (IOP).

205 teary eyes), and having adequate control of intraocular pressure (IOP).

206 bconjunctival drainage pathway and decreases intraocular pressure (IOP).

207 tural and functional damage, irrespective of intraocular pressure (IOP).

208 etic mutation causing glaucoma by increasing intraocular pressure (IOP).

209 ies associated with aging and sensitivity to intraocular pressure (IOP).

210 nal outflow function, the prime regulator of intraocular pressure (IOP).

211 Nitric oxide (NO) is able to lower intraocular pressure (IOP); however, its therapeutic eff

212 .3; 95% CI, 2.6-15.4; all P < 0.001), higher intraocular pressure (IOP; OR, 1.4; 95% CI, 1.1-1.8; P <

213 glaucoma or ocular hypertension (unmedicated intraocular pressure [IOP] >20 and <36 mm Hg at 8:00 AM)

214 idence of the hypertensive phase (defined as intraocular pressure [IOP] >21 mmHg during the first 3 p

215 Safety outcomes (intraocular pressure [IOP] elevation, cataract, and othe

216 Quantitative clinical measures (intraocular pressure [IOP], central corneal thickness [C

217 diabetes (T2D) and glaucoma-related traits (intraocular pressure [IOP], central corneal thickness [C

218 Corneal-compensated intraocular pressure (IOPcc) was measured with the Ocula

219 esistance factor (CRF), Goldmann- correlated intraocular pressure (IOPg), cornea-compensated IOP (IOP

220 on (Townsend index), and Goldmann-correlated intraocular pressure (IOPg).

221 medication and treated to predefined target intraocular pressures (IOPs) requiring >=20% IOP reducti

222 Elevated intraocular pressure is a highly heritable risk factor f

223 Treatment to lower intraocular pressure is based on topical drugs, laser th

224 Remarkably, intraocular pressure is significantly elevated in PrP(-/

225 rreversible blindness globally and for which intraocular pressure is the only modifiable risk factor.

226 cts up to 4.2 mm in diameter which generated intraocular pressure levels exceeding 1500 mmHg.

227 rgoing laser cyclophotocoagulation (CPC) for intraocular pressure lowering experienced these adverse

228 n a rabbit model of the disease achieving an intraocular pressure-lowering action comparable to the c

229 (UKGTS) demonstrated the effectiveness of an intraocular pressure-lowering drug in patients with glau

230 nds 11b-11d and 11g were evaluated for their intraocular pressure-lowering effects in a rabbit model

231 Intraocular pressure-lowering treatment use was similar

232 Sex, mean ocular perfusion pressure, intraocular pressure, mean deviation, and the quality sc

233 even 2 years after the operation; moreover, intraocular pressure measurement with ORA gives higher v

234 ected visual acuity, slitlamp biomicroscopy, intraocular pressure measurement, gonioscopy, dilated op

235 Intraocular pressure measurements between standard and a

236 lationships between corneal biomechanics and intraocular pressure measurements, which help elucidate

237 Intraocular pressure measures were obtained from Goldman

238 ded adverse events (AEs), visual acuity, and intraocular pressure monitoring, slit-lamp, dilated opht

239 t 40 min after the injection, well after the intraocular pressure normalized, the retinal and chorioc

240 Corticosteroid-associated AEs of elevated intraocular pressure occurred in 11.5% and 15.6% of the

241 r perforation, and no significant changes in intraocular pressure occurred.

242 n POAG eyes was associated with pretreatment intraocular pressure (odds ratio [OR] = 0.91/mm Hg highe

243 r AMD in the intervention eye, glaucoma with intraocular pressure of 25 mmHg or more, or other signif

244 nation, RE demonstrated light perception and intraocular pressure of 36 mmHg.

245 01) with good agreement between rise in mean intraocular pressure of the both eyes (dependent eye and

246 Data included clinical features (intraocular pressure, optic nerve obscuration, macular i

247 differences in the postoperative recovery of intraocular pressure or bleb morphology with or without

248 ive anterior uveitis patients with increased intraocular pressure or corneal edema seen at Kaohsiung

249 49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P =

250 40; 95% CI, 1.36-4.23;P = 0.003), and higher intraocular pressure (OR, 1.06; 95% CI, 1.02-1.09;P = 0.

251 mplex thickness was not associated with sex, intraocular pressure, or diabetes.

252 iated with decreased visual acuity, elevated intraocular pressure, or documentation of senolytic-rela

253 tically significant reductions from baseline intraocular pressure (P < .001), and was noninferior to

254 ressure (odds ratio [OR] = 0.91/mm Hg higher intraocular pressure, P = .06), VF mean deviation (MD, O

255 ease as a composite endpoint of elevation of intraocular pressure, peripheral anterior synechiae, or

256 pertension and megalocornea due to increased intraocular pressure provoked by Valsalva maneuver.

257 Acute increase in intraocular pressure, provoked by Valsalva maneuver is a

258 , best-corrected distance visual acuity, and intraocular pressure raised no safety concerns.

259 basic knowledge of AHO and possibly enhance intraocular pressure reduction after glaucoma surgery in

260 Oxidative stress contributes to both intraocular pressure regulation and glaucomatous neuropa

261 ansduction properties that may contribute to intraocular pressure regulation in the vertebrate eye.

262 In all cases, the mean visual acuity and intraocular pressures remained unchanged during conjunct

263 roup (91.3%), with glaucoma surgery to lower intraocular pressure required in none versus 11 patients

264 for studies exploring genetic influences on intraocular pressure responses to corticosteroid treatme

265 ments in ex vivo porcine cornea at different intraocular pressures reveal that Rev3D-OCE enables the

266 We have demonstrated that the elevated intraocular pressure seen in the uveitic glaucoma/OHT ey

267 Intraocular pressure-sensitive retinal ganglion cell deg

268 Intraocular pressure spike complication was defined as a

269 ient information including clinical (age and intraocular pressure), structural (cpRNFL thickness deri

270 ent including ocular massage and lowering of intraocular pressure, the visual loss remained.

271 nosensitive tissue in the eye that regulates intraocular pressure through the control of aqueous humo

272 Its management currently focuses on lowering intraocular pressure to slow disease progression.

273 related to treatment, and events of elevated intraocular pressure trended higher in the active group.

274 lensectomy-trabeculotomy) with a controlled intraocular pressure under topical quadritherapy and a b

275 Intraocular pressure values were calculated from the dee

276 Ophthalmic measures included intraocular pressure, visual field mean deviation, centr

277 gery were defined as good or satisfactory if intraocular pressure was <=16.0 mm Hg under anesthesia w

278 Mean change from baseline intraocular pressure was +2.6 vs +1.7 mm Hg (P = .52).

279 The mean presenting intraocular pressure was 22.9 mmHg in POAG and 25.5 mmHg

280 Intraocular pressure was 26 mmHg, despite maximal topica

281 The intraocular pressure was 28 mmHg, fundus exam revealed t

282 The mean preoperative intraocular pressure was 30.8 +/- 6.9 mmHg with 3.5 +/-

283 Corneal-compensated intraocular pressure was associated most significantly w

284 ive eye examination including measurement of intraocular pressure was conducted on postoperative day

285 entral retinal artery was detected after the intraocular pressure was elevated to 98 and >= 99 mmHg f

286 Intraocular pressure was estimated by analyzing videos r

287 The mean intraocular pressure was higher in Group 1 compared to t

288 Intraocular pressure was maintained with an anterior cha

289 Intraocular pressure was measured at each clinical visit

290 Intraocular pressure was measured at hours 0 and 2 at ea

291 His intraocular pressure was normal.

292 Elevated intraocular pressure was not included in the case defini

293 An objective target intraocular pressure was set according to glaucoma sever

294 Intraocular pressure was significantly associated with r

295 Raised intraocular pressure was the most common postoperative c

296 p < 0.0001, n = 153) while age, gender, and intraocular pressure were adjusted.

297 o-disc ratio, central corneal thickness, and intraocular pressure) were included.

298 ent showed mild keratopathy and elevation of intraocular pressure with topical NSAID and steroid ther

299 were able to achieve a reduction of >=20% in intraocular pressure without using hypotensive medicatio

300 ared with ED POAG patients, including higher intraocular pressure, worse visual acuity and visual fie